within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FD01_Trastuzumab;

model Trastuzumab
  extends Pharmacolibrary.Drugs.ATC.L.L01FD01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FD01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2/neu) and is primarily used in the treatment of HER2-positive breast cancer and metastatic gastric cancer. It is an approved therapy used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for adult female patients with HER2-positive metastatic breast cancer receiving intravenous trastuzumab. Parameters are for a typical patient as reported in published population pharmacokinetic studies.</p><h4>References</h4><ol><li><p>Okamoto, H, et al., &amp; Kuga, H (2020). Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 50(10) 1242–1250. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2020.1755909&quot;>10.1080/00498254.2020.1755909</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32306807/&quot;>https://pubmed.ncbi.nlm.nih.gov/32306807</a></p></li><li><p>Doi, T, et al., &amp; Tamura, K (2017). Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. <i>The Lancet. Oncology</i> 18(11) 1512–1522. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(17)30604-6&quot;>10.1016/S1470-2045(17)30604-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29037983/&quot;>https://pubmed.ncbi.nlm.nih.gov/29037983</a></p></li><li><p>Ismael, G, et al., &amp; Jackisch, C (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. <i>The Lancet. Oncology</i> 13(9) 869–878. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(12)70329-7&quot;>10.1016/S1470-2045(12)70329-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22884505/&quot;>https://pubmed.ncbi.nlm.nih.gov/22884505</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Trastuzumab;
